#Biocon started FY27 on a steady footing, with the Biopharma business as the key growth driver. Strong performance across geographies and the successful integration of biosimilars and generics businesses, contributed to this momentum. Q1 highlights: ➡️ Consolidated operating revenue increased 10% YoY to Rs 4,336 crore, driven by strong growth in the Biopharma business. ➡️ Biopharma revenue grew 17% YoY, driven by momentum from recent biosimilar and generic product launches across key markets. ➡️ Biosimilars revenue increased 16% YoY to Rs 2,855 crore. ➡️ Generics revenue increased 21% YoY Rs 760 crore. Read more: biocon.com/biocon-q1fy27-rev… #FY27Results #Q1FY27

Expansion of access begins with simple conversations. Starting tomorrow, from 6–8 October, the Biocon team will be on the ground at Fiera Milano, ready to discuss our established capabilities in biosimilars, complex APIs, and global-scale manufacturing. If you are looking for a reliable, long-term execution partner to help navigate the future of healthcare, we invite you to visit us. Meet us at Stand 7D34 to explore how our capabilities and global scale can support your ambitions. Let’s have a conversation. #Biocon #CPHIMilan2026 #PharmaManufacturing #Biosimilars #PatientAccess #GlobalScale #HealthcarePartnerships

“CPHI Worldwide is where the global pharmaceutical industry converges to showcase innovation, foster collaboration, and shape the future of healthcare. For Biocon, it is an opportunity to showcase the science, scale and quality that underpin our mission to expand access to high-quality, affordable medicines worldwide. From translating innovation into real-world impact to delivering consistently for patients, healthcare systems and partners across markets, our work is guided by a clear purpose: making healthcare more accessible to those who need it most. Realizing this requires meaningful partnerships that bring together complementary strengths, accelerate access to medicines, and extend the reach of innovation to underserved populations around the world. At CPHI Milan 2026, we look forward to strengthening existing collaborations, building new relationships, and exploring opportunities that create shared value while advancing patient access globally. If you're attending CPHI Milan, we invite you to meet Team Biocon and discover how, together, we can turn scientific progress into meaningful healthcare impact.” Deepali Naair (Global Head of Brand, Marketing & Corporate Communications) #Biocon #CPHIMilan2026 #HealthcareInnovation #GlobalPartnerships #PatientAccess #Pharmaceuticals #Biologics #Biosimilars #GlobalHealth #CPHI

“CPHI Milan brings together the global pharmaceutical community to exchange perspectives, strengthen collaborations and explore opportunities for long-term growth. For API customers, a sourcing decision extends beyond the molecule itself. It demands a partner capable of consistently aligning quality, cost and reliable delivery across markets and over the long term. Biocon’s API business is built to support these priorities through a broad portfolio, established regulatory credentials, proven manufacturing capability, and a sustained commitment to customer requirements. Today, the business spans more than 45 active APIs and is supported by 68 US Drug Master Files and 29 Certificates of Suitability. Its capabilities extend from fermentation-based statins and immunosuppressants to oncology high-potency APIs and GLP-1 peptides, with every programme underpinned by a commitment to customers’ launch plans. If you're attending CPHI Milan, we invite you to meet Team Biocon. Let’s explore opportunities for enduring collaboration.” - Amit Kaptain (Head – Global API Commercials & FDF – EM) #CPHI2026 #CPHIMilan #TeamBiocon #BioconAPI #PharmaceuticalIndustry #ActivePharmaceuticalIngredients #APIs #GlobalPharma

“Emerging markets are not one market — each requires a deep understanding of local healthcare needs, regulatory environments, access dynamics and the partnerships that make sustainable growth possible. Across Asia, the Middle East, Africa, CIS and Latin America, I have seen first-hand how combining local insights with global expertise can help expand access to high-quality, affordable medicines. At Biocon, we are building partnerships that bring together our scientific and manufacturing capabilities with strong local market understanding — with the shared objective of improving access for patients and strengthening healthcare systems. I look forward to meeting partners, customers and colleagues at CPHI Milan to explore opportunities to collaborate and expand access across emerging markets. If you are attending CPHI Milan, let’s connect.” - Ratish Trehan (Commercial Head – Emerging Markets) 📍 Fiera Milano | 6–8 October | Stand 7D34 #CPHI2026 #CPHIMilan #TeamBiocon #EmergingMarkets #HealthcareAccess #PharmaPartnerships

"Every year, I leave CPHI with the same thought: the most valuable insights rarely come from presentations. They come from conversations. This year, pharma professionals from 166+ countries will come together at CPHI Milan to discuss the challenges shaping the future of our industry. The question I'm most interested in is simple: How do we continue expanding access to high-quality medicines while helping more patients benefit from affordable treatment and supporting the sustainability of healthcare systems? There is no single answer. It takes innovation, scientific excellence, collaboration and a shared commitment to making healthcare more accessible and affordable. I'll be at CPHI Milan from 6-8 October with the Biocon team, meeting customers, partners and industry colleagues to exchange perspectives on the opportunities ahead. If you're attending, I'd be delighted to connect at Stand 7D34." Susheel Umesh Fiera Milano, Italy 6-8 October 2026 Stand 7D34 #CPHIMilan #CPHI2026 #Pharma #Healthcare #Partnerships #AccessToMedicines #Biocon

Representatives of leading pharma organisations from 166+ countries will gather at CPHI Milan 2026 to discuss one of the defining challenges facing healthcare today: how to improve access to high-quality medicines while meeting the growing needs of patients and healthcare systems worldwide. Biocon is proud to be at the forefront of addressing that challenge. As a global leader in affordable healthcare, our generic and biosimilar medicines benefited more than 23 million patients annually across 120+ countries in FY26. Across immunology, oncology, diabetes, ophthalmology, bone health, obesity and cardiovascular disease, we combine scientific and manufacturing excellence to help expand access to affordable, life-changing treatments, and support more sustainable healthcare systems. Join us at Stand 7D34 to explore how collaboration can help broaden patient access and shape the future of affordable healthcare. Fiera Milano, Italy 6-8 October 2026 #CPHIMilan #CPHI2026 #Biocon #Biosimilars #Pharma #Partnerships #AccessToMedicines #Healthcare

#ComingSoon: Biocon’s CEO & MD, Shreehas Tambe, in conversation with CNBC-TV18 at Biocon’s facility in Johor Bahru, Malaysia. Stay tuned for the full episode.

“Biocon delivered a resilient performance in Q1FY27, reporting consolidated revenue from operations growth of 10% year-on-year to Rs 4,336 crore and EBITDA of Rs 902 crore. This reflects the strength of our diversified portfolio and disciplined commercial execution. In FY27, we have successfully launched Bosaya™️ and Aukelso™️ (biosimilar Denosumab), Yesafili™️ (biosimilar Aflibercept), and generic Liraglutide, further strengthening our presence in the U.S. market. We also secured regulatory approval from the European Medicines Agency (EMA) for our new drug product fill-finish plant for insulins in Malaysia, unlocking additional manufacturing capacity. Our focus on balance sheet optimization reduced interest costs by 23% year-on-year. We expect growth momentum to accelerate through the year, driving a stronger second-half performance.” Shreehas Tambe, CEO & Managing Director, Biocon Limited Read more: lnkd.in/dmCdF_ES #FY27Result #Q1FY27

Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth and long-term value creation. A favourable policy environment for biosimilars together with our expanded manufacturing capabilities in the U.S. reinforce our confidence in the long-term opportunities across North America, our biggest market. We also remain confident that the investments in new capabilities at our research services business will support its next phase of growth.” @kiranshaw, Executive Chairperson, Biocon Limited Read more: biocon.com/biocon-q1fy27-rev… #Biocon #FY27Results #Q1FY27

Being a good leader starts with fairness, honesty and helping people grow. Watch @kiranshaw in conversation with Navika Kumar on leadership, entrepreneurship and purpose.

Nearly 2.6 million new lung cancer cases were estimated worldwide in 2024, making it the world's most commonly diagnosed cancer. For millions of patients, progress in cancer care is only meaningful when treatment is within reach. At Biocon, we support efforts that help people access treatment. #WorldLungCancerDay #LungCancer #Oncology #CancerCare #Biocon

Scientific progress has broadened treatment options for head and neck cancer. Targeted therapies are an important part of these treatments, helping prevent tumour growth. As they become an integral part of cancer care, it is vital to help more patients benefit from them. At Biocon, we are helping expand access to established oncology therapies through high-quality biosimilars for patients around the world. #WorldHeadAndNeckCancerDay #HeadAndNeckCancer #Oncology #CancerCare #Biocon

As our understanding of cancer has advanced, so has the science behind its treatment. ​ Today, biosimilars are helping expand access to life-changing therapies developed through decades of scientific research and innovation.​ See how Biocon is helping bring the frontiers of cancer care to the people who need it most in #RewritingCancer. ​ Watch now: youtu.be/aHQPF1S98rc?si=Ai_F…​ ​ #RewritingCancer #Biocon #Biosimilars #CancerCare #Oncology ​ Disclaimer: This content is for educational purposes only and is not medical advice. Consult a healthcare professional for treatment decisions. The experiences described are individual and may not be representative of all patients.

She had a plan for her future.​ Cancer wasn't part of it. ​ In #RewritingCancer, presented by @uicc and produced by @BBCStoryWorks, follow one patient's journey and see the impact that advances in cancer care can have in creating new possibilities for more people.​ Watch now: youtu.be/aHQPF1S98rc #RewritingCancer #Biocon #Biosimilars #CancerCare #Oncology​ Disclaimer: This content is for educational purposes only and is not medical advice. Consult a healthcare professional for treatment decisions. The experiences described are individual and may not be representative of all patients.